Role of the Methoxy Group in Immune Responses to mPEG-Protein Conjugates
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Anti-PEG antibodies have been reported to mediate the accelerated clearance of PEG-conjugated proteins and liposomes, all of which contain methoxyPEG (mPEG). The goal of this research was to assess the role of the methoxy group in the immune responses to mPEG conjugates and the potential advantages of replacing mPEG with hydroxyPEG (HO-PEG). Rabbits were immunized with mPEG, HO-PEG, or t-butoxyPEG (t-BuO-PEG) conjugates of human serum albumin, human interferon-α, or porcine uricase as adjuvant emulsions. Assay plates for enzyme-linked immunosorbent assays (ELISAs) were coated with mPEG, HO-PEG, or t-BuO-PEG conjugates of the non-cross-reacting protein, porcine superoxide dismutase (SOD). In sera from rabbits immunized with HO-PEG conjugates of interferon-α or uricase, the ratio of titers of anti-PEG antibodies detected on mPEG-SOD over HO-PEG-SOD ("relative titer") had a median of 1.1 (range 0.9-1.5). In contrast, sera from rabbits immunized with mPEG conjugates of three proteins had relative titers with a median of 3.0 (range 1.1-20). Analyses of sera from rabbits immunized with t-BuO-PEG-albumin showed that t-butoxy groups are more immunogenic than methoxy groups. Adding Tween 20 or Tween 80 to buffers used to wash the assay plates, as is often done in ELISAs, greatly reduced the sensitivity of detection of anti-PEG antibodies. Competitive ELISAs revealed that the affinities of antibodies raised against mPEG-uricase were c. 70 times higher for 10 kDa mPEG than for 10 kDa PEG diol and that anti-PEG antibodies raised against mPEG conjugates of three proteins had >1000 times higher affinities for albumin conjugates with c. 20 mPEGs than for analogous HO-PEG-albumin conjugates. Overall, these results are consistent with the hypothesis that antibodies with high affinity for methoxy groups contribute to the loss of efficacy of mPEG conjugates, especially if multiply-PEGylated. Using monofunctionally activated HO-PEG instead of mPEG in preparing conjugates for clinical use might decrease this undesirable effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was found that the methoxy group of the mPEG-protein contributed to a significantly higher immune response than that of hydroxy group of HO-PEG.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [81]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Ansar Ahmed, S., Gogal, R. M., & Walsh, J. E. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90396-4 · Cited by 1,359
Abuchowski, A., van Es, T., Palczuk, N. C., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40291-2 · Cited by 1,358
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Kitamura, T., Tange, T., Terasawa, T., Chiba, S., Kuwaki, T., Miyagawa, K., Piao, Y., Miyazono, K., Urabe, A., & Takaku, F. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041400219 · Cited by 784
Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
FDA-approved poly(ethylene glycol)–protein conjugate drugs
Alconcel, S. N. S., Baas, A. S., & Maynard, H. D. (2011) · Polymer Chemistry · doi:10.1039/c1py00034a · Cited by 643
Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 607
The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics
Fishburn, C. S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21278 · Cited by 474
PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner
Ishida, T., Wang, X., Shimizu, T., Nawata, K., & Kiwada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.015 · Cited by 382
Ganson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S., & Hershfield, M. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1861 · Cited by 350
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
Sherman, M. R., Saifer, M. G. P., & Perez-Ruiz, F. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.011 · Cited by 291
Self-citationRichter, A. W., & Åkerblom, E. (1983) · International Archives of Allergy and Immunology · doi:10.1159/000233309 · Cited by 282
Judge, A., McClintock, K., Phelps, J. R., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.014 · Cited by 280
Polymer therapeutics as nanomedicines: new perspectives
Duncan, R. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.05.507 · Cited by 254
Richter, A. W., & Åkerblom, E. (1984) · International Archives of Allergy and Immunology · doi:10.1159/000233512 · Cited by 229
Sundy, J. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Rehrig, C. D., Huang, W., & Hershfield, M. S. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22403 · Cited by 221
Semple, S. C., Harasym, T. O., Clow, K. A., Ansell, S. M., Klimuk, S. K., & Hope, M. J. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078113 · Cited by 211
Gene expression analysis of purified hematopoietic stem cells and committed progenitors
Terskikh, A. V., Miyamoto, T., Chang, C., Diatchenko, L., & Weissman, I. L. (2003) · Blood · doi:10.1182/blood-2002-08-2509 · Cited by 199
Sundy, J. S., Becker, M. A., Baraf, H. S. B., Barkhuizen, A., Moreland, L. W., Huang, W., Waltrip, R. W., Maroli, A. N., Horowitz, Z., & Pegloticase Phase 2 Study Investigators (2008) · Arthritis & Rheumatism · doi:10.1002/art.23810 · Cited by 181
Pharmacokinetics and Pharmacodynamics of Pegfilgrastim
Yang, B.-B., & Kido, A. (2011) · Clinical Pharmacokinetics · doi:10.2165/11586040-000000000-00000 · Cited by 161
Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases
NG, E. W. M., & ADAMIS, A. P. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1348.062 · Cited by 161
Antiproliferative Properties of Type I and Type II Interferon
Bekisz, J., Baron, S., Balinsky, C., Morrow, A., & Zoon, K. C. (2010) · Pharmaceuticals · doi:10.3390/ph3040994 · Cited by 150
Accelerated Clearance of Polyethylene Glycol-Modified Proteins by Anti-Polyethylene Glycol IgM
Cheng, T.-L., Wu, P.-Y., Wu, M.-F., Chern, J.-W., & Roffler, S. R. (1999) · Bioconjugate Chemistry · doi:10.1021/bc980143z · Cited by 147 · cited 1×
“(15) Cheng, T.-L., Wu, P.-Y., Wu, M.-F., Chern, J.-W., and Roffler, S. R. (1999) Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM.”
Trainer, P. J., Ezzat, S., D’Souza, G. A., Layton, G., & Strasburger, C. J. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03620.x · Cited by 140
Ishida, T., Kashima, S., & Kiwada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.11.009 · Cited by 125
Müller, H., Löning, L., Horn, A., Schwabe, D., Gunkel, M., Schrappe, M., Von Schütz, V., Henze, G., Casimiro da Palma, J., Ritter, J., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02187.x · Cited by 120
Repeated injections of PEG-PE liposomes generate anti-PEG antibodies.
Środa-Pomianek, K., Rydlewski, J., Langner, M., Kozubek, A., Grzybek, M., & Sikorski, A. F. (2005) · PubMed · Cited by 116
Gaspar, B. (2009) · Biologics: Targets & Therapy · doi:10.2147/btt.2009.3286 · Cited by 106
Determination of Polyethylene Glycols 4000 and 6000 in Plasma Protein Preparations
Skoog, B. (1979) · Vox Sanguinis · doi:10.1111/j.1423-0410.1979.tb02314.x · Cited by 101
Su, Y.-C., Chen, B.-M., Chuang, K.-H., Cheng, T.-L., & Roffler, S. R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100067t · Cited by 92
Cheng, T.-L., Cheng, C.-M., Chen, B.-M., Tsao, D.-A., Chuang, K.-H., Hsiao, S.-W., Lin, Y.-H., & Roffler, S. R. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050133f · Cited by 91
Pegloticase and Chronic Gout--Reply
Sundy, J. S., Becker, M. A., & White, W. B. (2011) · JAMA · doi:10.1001/jama.2011.1617 · Cited by 82
Methoxy Polyethylene Glycol-Epoetin Beta
Curran, M. P., & McCormack, P. L. (2008) · Drugs · doi:10.2165/00003495-200868080-00009 · Cited by 81
Armstrong, J. K. (2009) · PEGylated Protein Drugs: Basic Science and Clinical Applications · doi:10.1007/978-3-7643-8679-5_9 · Cited by 72
Kitamura, T., Takaku, F., & Miyajlma, A. (1991) · International Immunology · doi:10.1093/intimm/3.6.571 · Cited by 70
Cheng, T.-L., Chen, B.-M., Chern, J.-W., Wu, M.-F., & Roffler, S. R. (2000) · Bioconjugate Chemistry · doi:10.1021/bc990147j · Cited by 67 · cited 1×
“(16) Cheng, T.-L., Chen, B.-M., Chern, J.-W., Wu, M.-F., and Roffler, S. R. (2000) Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy.”
Porstmann, B., Porstmann, T., & Nugel, E. (1981) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1981.19.7.435 · Cited by 65
Recombinant human leukocyte interferon produced in bacteria has antiproliferative activity.
EVINGER, M. J. Q., Maeda, S., & Pestka, S. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69745-0 · Cited by 64
Suppression of Reaginic Antibodies with Modified Allergens
Lee, W. Y., & Sehon, A. H. (2009) · International Archives of Allergy and Applied Immunology · doi:10.1159/000232023 · Cited by 63
Garratty, G. (2008) · Vox Sanguinis · doi:10.1111/j.1423-0410.2007.01003.x · Cited by 62
On-line characterization of polyethylene glycol-modified proteins
Kunitani, M. G., Dollinger, G. D., Johnson, D., & Kresin, L. (1991) · Journal of Chromatography A · doi:10.1016/0021-9673(91)85014-7 · Cited by 56
Suppression of Reaginic Antibodies with Modified Allergens
Lee, W. Y., & Sehon, A. H. (2009) · International Archives of Allergy and Applied Immunology · doi:10.1159/000232019 · Cited by 49
Sensitive Measurement of Polyethylene Glycol-Modified Proteins
Tsai, N., Cheng, T., & Roffler, S. R. (2001) · BioTechniques · doi:10.2144/01302rr03 · Cited by 26
Hatfield, R. M., Morris, B. A., & Henry, R. R. (1987) · Avian Pathology · doi:10.1080/03079458708436358 · Cited by 23
Wedekin, M., Ehrich, J. H. H., & Pape, L. (2011) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2011.01476.x · Cited by 14
Collaborative study for the establishment of erythropoietin BRP batch 3.
Behr-Gross, M.-E., Daas, A., Burns, C. J., & Bristow, A. F. (2007) · PubMed · Cited by 10
Research works printed but not linked: 4
- Środa K., 2005, Cell. Mol. Biol. Lett., 10, 37
- Porstmann B., 1981, J. Clin. Chem. Clin. Biochem., 19, 435
- Behr-Gross M.-E., 2007, Pharmeuropa Bio., 2007, 49
- Booth C., 2009, Biologics, 3, 349
Cited by
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
“Antibodies preferentially bound to the PEG backbone when the end functional group was a hydroxyl, and with lesser affinity than binding to methoxy functionalized PEG conjugates [108, 109].”
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
“[154] Likewise, hydroxyl-PEG conjugated to porcine uricase exhibited lower immunogenicity compared with mPEG.[155] Another suggested strategy is administration of short oligomers of PEG prior to the PEGylated drug to avoid formation of immune complexes.”
BackgroundEffects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery
Shi, L., Zhang, J., Zhao, M., Tang, S., Cheng, X., Zhang, W., Li, W., Liu, X., Peng, H., & Wang, Q. (2021) · Nanoscale · doi:10.1039/d1nr02065j · Cited by 808
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696
Metadata
- Authors
- Sherman, M. R., Williams, L. D., Sobczyk, M. A., Michaels, S. J., & Saifer, M. G. P.
- Affiliations
- Edison Pharmaceuticals (United States) (US)
- Corresponding author
- Sherman, Merry R.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-03-07
- Volume
- 23
- Issue
- 3
- Pages
- 485-499
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- PMC
- PMC3309606
- OpenAlex
- W64311466
- Cited by
- 185
- References
- 53
- Citations by year
- 2026: 14 · 2025: 26 · 2024: 13 · 2023: 14 · 2022: 16 · 2021: 13 · 2020: 13 · 2019: 12 · 2018: 10 · 2017: 7 · 2016: 12 · 2015: 12 · 2014: 8 · 2013: 8 · 2012: 7
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Bioconjugate Chemistry (publishedVersion, other-oa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- anti-PEG antibodies, PEGylation, immune response, antibody affinity, human serum albumin, interferon-alpha, uricase, superoxide dismutase
- MeSH terms
- Animals, Enzyme-Linked Immunosorbent Assay, Humans, Polyethylene Glycols, Proteins, Rabbits, Interferon-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.